Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Benefits of Metformin Add-On Insulin Therapy (Mait) for Hba1c and Lipid Profile in Adolescents With Type 1 Diabetes Mellitus: Preliminary Report From a Double-Blinded, Placebo-Controlled, Randomized Clinical Trial Publisher Pubmed



Sheikhy A1, 2 ; Eydian Z3 ; Fallahzadeh A1, 2 ; Shakiba M3 ; Hajipour M4 ; Alaei M3 ; Mosallanejad A5 ; Saneifard H3, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Research Department, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  4. 4. Pediatric Gastroenterology, Hepatology and Nutrition Research Center, Research Institute for Children's Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  5. 5. Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Journal of Pediatric Endocrinology and Metabolism Published:2022


Abstract

Objectives: Metabolic control during puberty is impaired in Type 1 Diabetes Mellitus (T1DM) patients due to increased insulin resistance. Metformin is one of the oral medications typically used in type 2 diabetes mellitus to reduce insulin resistance. We aimed to examine the effect of metformin on glycemic indices and insulin daily dosage in adolescents with T1DM. Methods: The present clinical trial was carried out on 50 adolescents aged 10-20 years with T1DM referred to the Endocrinology Clinic of Mofid Children's Hospital in Tehran for nine months. The patients were randomly divided into two groups. In the first group, metformin was added to insulin therapy, while the second group continued routine insulin therapy combined with placebo. Hemoglobin A1c (HbA1c), weight, BMI, insulin dosage, and blood pressure were measured at the beginning of the study and repeated every three months. Serum lipid profile, creatinine, blood urea nitrogen, and liver enzymes were also measured twice: At the beginning and end of the study (after nine months). Results: The HbA1c level (p<0.001) and insulin dosage (p=0.04) were lower in the metformin group than in the placebo group after nine months. Daily insulin dosage variability was significantly lower in the metformin recipient group (p=0.041). Serum triglyceride, cholesterol, and creatinine were significantly lower in the metformin arm than in the placebo arm (p<0.05). However, metformin did not affect LDL, HDL, liver enzymes, and BUN. Conclusions: Adjunctive metformin therapy reduces insulin dosage by inhibiting insulin resistance and weight gain. It helps decrease daily insulin dosage variability, which may prevent hypoglycemia. Also, metformin reduces creatinine, preventing renal failure in the long term. © 2022 Walter de Gruyter GmbH, Berlin/Boston.